Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy

18 Years and older

Yes

No

Non Hodgkin Lymphoma stage III or IV at timepoint of diagnosis

Yes

No

Patients who have achieved a remission after first line chemotherapy

Yes

No

No less than 6 weeks and no more than 12 weeks since last dose of chemotherapy

Yes

No

written informed consent

Yes

No

Any other anticancer treatment for NHL except the preceding first line chemotherapy

Yes

No

Prior radiation therapy

Yes

No

Patients who have not recovered from the toxic effects of the first line chemotherapy

Yes

No

Any other cancer or history of cancer less than 10 years ago

Yes

No

Patients with known HIV positivity

Yes

No

patients with pleural effusion or ascites

Yes

No

female patients who are pregnant or breast feeding (women of childbearing potential must have a negative serum pregnancy test at study entry)

Yes

No

Adults not employing an effective method of birth control during study treatment and 12 months thereafter

Yes

No

Patients unable or unwilling to comply with protocol

Yes

No